Viread took a step faster on the drug price reduction

‘Viread(generic name: tenofovir),’ a chronic type B hepatitis treatment, will took a step faster than ‘Baraclude(generic name: entecavir),’ which will face patent expiration on the coming October, on the drug price reduction.

According to the pharmaceutical industry, ceiling price of the Viread’s insurance benefit will be decreased by KRW 375(7.095%) from KRW 5,285 to KRW 4,910 from the 1^st ne...